NOVEL ORAL COMBINATION CHEMOTHERAPY (CT) IN THE MANAGEMENT OF AIDS-RELATED NON-HODGKIN'S LYMPHOMA (NHL) (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

NOVEL ORAL COMBINATION CHEMOTHERAPY (CT) IN THE MANAGEMENT OF AIDS-RELATED NON-HODGKIN'S LYMPHOMA (NHL) (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 10:A2 1991. Unique Identifier : AIDSLINE ICDB/91671488
Remick S; McSharry J; Wolf B; Blanchard C; Gorman P; Slaga J; Wagner H; Harper G; Horton J; Ruckdeschel J; Albany Medical Coll., Albany, NY 12208

Abstract: We are administering an oral-based combination CT regimen to patients (pts) with AIDS-related NHL repeated at 6-wk intervals consisting of CCNU 100 mg/m2 day 1 (cycles 1, 3, 5), VP-16 200 mg/m2 days 1-3, cyclophosphamide 100 mg/m2 days 22-31, and procarbazine 100 mg/m2 days 22-31. Nine male pts with good performance status and biopsy-proven NHL were entered. In 8, NHL was the AIDS-defining illness and 7 had Stage III or IV disease. A total of 18 cycles of therapy was administered with a median of 1.5 per pt (range 0.5 to 4). The regimen is myelosuppressive with a total of 9 episodes of grade 4 neutropenia of which 5 were associated with fever, and 1 episode of grade 4 thrombocytopenia. There has been 1 febrile neutropenic death associated with a rapidly progressive cardiomyopathy. Except for alopecia there has been no other severe toxicity. There have been 3 complete responses (7, 7, and 12 mo since on-study) and 1 partial response for an objective response rate of 50% (1 pt too early). Flow cytometric detection of fluorescently labeled monoclonal antibody to p24 antigen of peripheral blood mononuclear cells (PBMC) has been studied in 5 pts to assess the impact of therapy on HIV antigenemia. Median percent p24-positive PBMC was 5.17% (range 1.07-12.69%). A pt is considered positive for p24 antigen when employing this technique when greater than or equal to 4% of PBMC are positive. This regimen can be readily given to outpatients, is active and, except for myelosuppression, is well tolerated.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Administration, Oral Alopecia/CHEMICALLY INDUCED Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE Cyclophosphamide/ADMINISTRATION & DOSAGE Etoposide/ADMINISTRATION & DOSAGE Human Lomustine/ADMINISTRATION & DOSAGE Lymphoma, Non-Hodgkin's/*DRUG THERAPY/ETIOLOGY Male Procarbazine/ADMINISTRATION & DOSAGE ABSTRACT
910930
M9190742

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .